TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06396741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The quadriceps muscle will be punctured with ultrasound control
Description: With the subject in the supine position, the quadriceps muscle will be shown by ultrasound. Subsequently, a dry needling technique will be performed at the most hyperalgesic point using ultrasound control.
Study: NCT05528640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health Literacy Program
Description: Six educational sessions will be delivered on a private YouTube channel which consists of information about mental health literacy (knowledge about priority mental illnesses, attitude/ stigma related to mental illnesses, and help-seeking efficacy). There will be six-weeks unrestricted access period. Afterwards, the round-up session which consists of problem-based learning and group sharing will be delivered in person. Two vignettes based on the clinical scenarios will be given for discussion. Furthermore, participants are encouraged to share their opinion on mental health literacy, strategies for dealing with difficulties of caring for patients with mental illnesses in general hospitals, way to promote mental health literacy of healthcare professionals in general hospitals
Study: NCT04764630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Four naloxone nasal spray doses (1 every 2.5 min)
Description: Four 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min, left nostril at 5 min, right nostril at 7.5 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Four naloxone nasal spray doses (2 every 2.5 min)
Description: Four 4 mg IN naloxone doses (left and right nostrils at 0 min, left and right nostrils at 2.5 min)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two naloxone nasal spray doses (1 every 2.5 min)
Description: Two 4 mg IN naloxone doses (left nostril at 0 min, right nostril at 2.5 min)
Study: NCT06629389

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The following dose regime for the 4 treatment arms will be used:~DOSE TITRATION PERIOD:~First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The first 7 days dose will be reduced to 0.5 mL/day; on subsequent 7 days, dose will be reduced to 0.3 mL/day. If a patient has reached a maximum tolerated dose, dose reduction will be made at the discretion of the investigator.
Study: NCT06695117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIV-HD
Description: Inactivated, split-virion
Study: NCT05036824

Intervention type: DRUG
Intervention: tinzaparin
Description: Daily tinzaparin administration: 8000 - 14000 Anti-Xa IU
Study: NCT06159309

Intervention type: OTHER
Intervention: Hyperbaric oxygen therapy
Description: HBOT per local protocol, i.e. 40 sessions 2.4 ATA, at the discretion of the hyperbaric physician
Study: NCT05646628

Intervention type: BEHAVIORAL
Intervention: Qualitative Interviews
Description: Semi-structured Qualitative Interviews
Study: NCT05983666

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Oesophageal Intubation
Description: Ultrasound Oesophageal intubation detection
Study: NCT06695117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIV-HD
Description: Inactivated, split-virion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rC19 (dose 1)
Description: Protein subunit
Study: NCT04800341

Intervention type: OTHER
Intervention: Questionnaire
Description: Structured questionnaire to collect cardiovascular and metabolic events, incident cancers and deaths that have occured, as weel as information on CPAP, through telephone interview.
Study: NCT05789758

Intervention type: OTHER
Intervention: No Intervention
Description: Administered as specified in the treatment arm.
Study: NCT04762940

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic
Description: The Amadeo® Manual Robotic System (Tyromotion GmbH, Graz, Austria) is designed for rehabilitative treatment of the hand and fingers providing robot-assisted exercise for the finger flexors and extensors. This system has a controlled position, active, active-assisted and passive exercise mode, it also allows isometric exercises with visual feedback provided during computerized games that emphasize flexion and extension.~Robotic treatment will be conducted three times a week with 24 sessions (a month and a half of treatment) with assisted therapy: It allows to carry out the movement by force of the fingers themselves, compensating the range of movement that the user does not perform; and interactive therapy: it allows to carry out active finger movement oriented to tasks or games. These can be configured to adapt them as much as possible to the capabilities of the user.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic
Description: The Amadeo® Manual Robotic System (Tyromotion GmbH, Graz, Austria) is designed for rehabilitative treatment of the hand and fingers providing robot-assisted exercise for the finger flexors and extensors. This system has a controlled position, active, active-assisted and passive exercise mode, it also allows isometric exercises with visual feedback provided during computerized games that emphasize flexion and extension.~Robotic treatment will be conducted three times a week with 24 sessions (a month and a half of treatment) with assisted therapy: It allows to carry out the movement by force of the fingers themselves, compensating the range of movement that the user does not perform; and interactive therapy: it allows to carry out active finger movement oriented to tasks or games. These can be configured to adapt them as much as possible to the capabilities of the user.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Vibration duration of approximately 20 minutes with a high vibration frequency will be conducted prior to robotic treatment. The intensity and timing of this treatment has been based on previous protocols, as previously justified in this project. Vibration therapy, with proprioceptive stimuli through sensors placed on the distal phalanges of the fingers, modulation from lower to higher frequency being possible (high frequency vibration of 300 Hz).
Study: NCT04792879

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peripheral veins Doppler ultrasound
Description: Patients undergoing a right heart catheterization for PH diagnosis or annual follow-up in the cardiological unit of the university hospital of Poitiers will be included. A venous Doppler ultrasound will be performed by a vascular physician, with experience in vascular ultrasound imaging, within 4 hours before the right heart catheterization. Morphological parameters of vena cava, and velocimetric parameters of femoral, jugular and supra-hepatic veins will be assessed in order to study their correlation with right auricular pressure value.
Study: NCT05116748

Intervention type: BIOLOGICAL
Intervention: COVID19 mRNA vaccine
Description: Administration of COVID19 mRNA vaccine
Study: NCT06695117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rC19 (dose 1)
Description: Protein subunit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIV-HD + rC19 (dose 1)
Description: IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIV-HD + rC19 (dose 2)
Description: IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIV-HD + rC19 (dose 3)
Description: IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IIV-HD + rC19 (dose 4)
Description: IIV-HD component: Inactivated, split-virion rC19 component: Protein subunit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% NaCl)
Description: Normal saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% NaCl)
Description: Normal saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% NaCl)
Description: Normal saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% NaCl)
Description: Normal saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% NaCl)
Description: Normal saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (0.9% NaCl)
Description: Normal saline
Study: NCT06440252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grape Seed Extract
Description: One daily dose of 1 capsule containing 600mg grape seed extract

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: One daily dose of 1 capsule
Study: NCT06716736

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: socket preservation using dentine graft mixed with i-PRF
Description: surgical extraction of horizontally impacted third molar , placement of dentin graft mixed with i-PRF inside the socket , suturing

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: socket preservation using bone allograft
Description: surgical extraction of horizontally impacted third molar , placement of bone allograft inside the socket , suturing

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: socket preservation using collagen cone
Description: surgical extraction of horizontally impacted third molar , placement of collagen cone inside the socket , suturing
Study: NCT06412770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai chi
Description: Participants will be asked to do Tai Chi for 30 minutes three times a week

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Tai Chi imagery
Description: Participants will be asked to do Tai Chi imagery for 30 minutes three times a week

Intervention type: OTHER
Group type: OTHER
Intervention: no-intervention
Description: The comparison group will be given usual care
Study: NCT04951362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal spray ivermectin
Description: intranasal spray of saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intranasal spray ivermectin
Description: intranasal spray of saline
Study: NCT05911581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intra-arterial flushing
Description: The catheter will be flushed to prevent occlusion after radial artery catheterization.~intra-arterial flushing with heparinized fluid kept in room air

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intra-arterial flushing
Description: Intra-arterial flushing with heparinized fluid at patient body temperature
Study: NCT05344924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE+penpulimab+anlotinib vs. penpulimab+anlotinib
Description: Patients will receive TACE as needed; penpulimab 200 mg i.v. every 3 weeks(Q3W); and anlotinib 12 mg orally before breakfast,everyday(QD); continue taking for 2 weeks and stop for 1 week, that is, 3 weeks (21 days) as a course of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE+penpulimab+anlotinib vs. penpulimab+anlotinib
Description: Patients will receive TACE as needed; penpulimab 200 mg i.v. every 3 weeks(Q3W); and anlotinib 12 mg orally before breakfast,everyday(QD); continue taking for 2 weeks and stop for 1 week, that is, 3 weeks (21 days) as a course of treatment.
Study: NCT06711627

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SoC)
Description: Standard recommended nutrition and gestational weight gain counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Provision
Description: Standard recommended nutrition and gestational weight gain counseling plus food provision.
Study: NCT06717061

Intervention type: PROCEDURE
Intervention: Harvesting of biological material
Description: During the sampling of biological material, the test subjects will be under general anesthesia, which is why the sampling will not mean increased pain or discomfort other than what is standard after a gallbladder operation with the peephole technique. . The sampling is not planned to be repeated, but is performed at the time when the patients perform their biliary surgery. During the sampling, centimeter-sized pieces of skin, fatty tissue, connective tissue and muscle are taken. Furthermore, serum and plasma will be collected. Two tubes of blood samples (10 ml total) are taken, centrifuged and pipetted before being frozen for later analysis. Pieces of tissue are placed in formalin before transport to the laboratory. The study form regarding the patient\&#39;s basic state of health will be filled in by the operator on the day of surgery.
Study: NCT06719284

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HFO&VTV at targeted tidal volumes of 1.5, 2.0 and 2.5 ml/kg in random order
Description: HFO\&VTV at targeted tidal volumes of 1.5, 2.0 and 2.5 ml/kg in random order

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HFOV at the settings applied prior to the study
Description: HFOV at the settings applied prior to the study
Study: NCT06716125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic treadmill walking plus low calorie diet
Description: this group (n =20 for the group) will administer low calorie diet for 12 weeks plus additionally administering supervised walking treadmill aerobic training for 45 minutes 3 times per week for 12 weeks).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low calorie diet
Description: this group (n =20 for the group) will administer low calorie diet for 12 weeks
Study: NCT06718218

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Pain Management
Description: Participants will listen to a 5-minute audio recording of a mindfulness exercise consisting of a 1-minute introduction to mindful pain management and a 4-minute mindfulness practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Recording With Sustained Tone
Description: Participants will listen to a 5-minute audio recording of a mindfulness exercise consisting of a 1-minute introduction to mindful pain management and a 4-minute mindfulness practice, that is accompanied by a sustained low C tone at 65.41 Hertz.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Recording with Binaural Beats
Description: Participants will listen to a 5-minute audio recording of a mindfulness exercise consisting of a 1-minute introduction to mindful pain management and a 4-minute mindfulness practice that is accompanied by binaural beats resulting from the delivery of a sustained 65.41 Hertz tone in the left ear and a sustained 69.41 Hertz tone in the right ear.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Recording with Binaural Beats and Theta Music
Description: Participants will listen to a 5-minute audio recording of a mindfulness exercise consisting of a 1-minute introduction to mindful pain management and a 4-minute mindfulness practice that is accompanied by binaural beats resulting from the delivery of a sustained 65.41 Hertz tone in the left ear and a sustained 69.41 Hertz tone in the right ear as well as instrumental theta wave music.
Study: NCT06715319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA
Description: OCA 5 mg once daily in combination with UDCA for 12 weeks and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Description: 13\~15 mg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UDCA
Description: 13\~15 mg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once a day (QD) by mouth (PO)
Study: NCT04900038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 was available as 25 mg or 100 mg tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 was available as 25 mg or 100 mg tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 was available as 25 mg or 100 mg tablets administered orally.
Study: NCT05208242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperoncotic human albumin solution
Description: 20% human albumin solution (presented in 100ml glass bottles)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buffered crystalloid solutions
Description: Buffered crystalloids solutions for all intravenous fluid therapy
Study: NCT06514222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given together every 8 hours
Description: Group 1- The patient will receive 400mg ibuprofen plus 1000mg Paracetamol simultaneously every 8 hours for two days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol and Ibuprofen. The combination of the Paracetamol and Ibuprofen will be given alternatively every four hours
Description: Group 2- The patient will receive 400mg ibuprofen and 1000mg Paracetamol at 4 hours in intervals for two days. With a total of 3 doses of ibuprofen and 3 doses of paracetamol per day
Study: NCT06717386

Intervention type: PROCEDURE
Group type: OTHER
Intervention: diagonal pelvic osteotomy
Description: supraacetabular pelvic osteotomy in oblique shape

Intervention type: PROCEDURE
Group type: OTHER
Intervention: diagonal pelvic osteotomy
Description: supraacetabular pelvic osteotomy in oblique shape
Study: NCT06717334

Intervention type: DIAGNOSTIC_TEST
Intervention: Low Dose CT imaging
Description: at baseline and at Year 1.

Intervention type: OTHER
Intervention: blood draws
Description: at baseline and at Year 1.
Study: NCT05162651

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency-management
Description: In addition to structured assessments at baseline, four, eight and twelve months, subjects randomized to the contingency-management group will receive a contingent bonus if the participants show successful abstinence at the end of weeks 4, 8 and 12.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced usual care
Description: Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve weeks.
Study: NCT04710537

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AlloDerm
Description: Enrolled patients will have one of their breasts reconstructed with AlloDerm at the time of their breast reconstruction surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DermACELL
Description: Enrolled patients will have one of their breasts reconstructed with DermACELL at the time of their breast reconstruction surgery.
Study: NCT04900038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir
Description: DTG was available as 50 mg tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: DTG was available as 50 mg tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: DTG was available as 50 mg tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: DTG was available as 50 mg tablets administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine capsules
Description: 3TC was available as 300 mg capsules administered orally as a blinded treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine tablets
Description: 3TC was available as 300 mg tablets administered orally as an unblinded treatment.
Study: NCT06717204

Intervention type: DRUG
Intervention: Vericiguat Oral Tablet [Verquvo]
Description: Vericiguat in addition to conventional treatment

Intervention type: DRUG
Intervention: Prescription Drugs
Description: Conventional treatment only
Study: NCT06269289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web based education
Description: Training presentations will be prepared in 5 modules by taking expert opinions in line with the literature. Training will be aimed at empowering patients to control asthma. It will include topics such as medication use, device use, exercise and disease management. Each week, an intervention group will be invited online to a module and the training will be given by the researcher.
Study: NCT06717204

Intervention type: DRUG
Intervention: Prescription Drugs
Description: Conventional treatment only
Study: NCT06717360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG2304T
Description: AG2304T, QD, PO
Study: NCT05418075

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: If the families agree to participate in the study, they are randomly assigned to a treatment group. In each of the three groups, they are treated with FBT in a weekly session. In the two comparison groups, Hometreatment or MBSR are offered in addition to FBT, with two consultations per week in each case.
Study: NCT06717360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG2304R
Description: AG2304R, QD, PO
Study: NCT06718556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The virtual reality intervention program was carried out in a 30-meter2 area covered with soft ground to prevent injuries. The Microsoft Kinect for Xbox 360 was used for the virtual reality intervention. For the current study, a team of experts was formed to select the games to be used within the virtual reality intervention program. This team determined which skills were required for the games to be run successfully, which skills could be developed, which games were purposeful, and independently observed each game. As a result, 9 different games were chosen. Since all games involve similarly intense visual, cognitive and motor skill requirements, game selection was left to the participants' preference during the intervention process to encourage motivation and participation. The virtual reality intervention procedure was created by utilizing the literature

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Client-centered
Description: The client-centered (CC) intervention procedure for individuals with schizophrenia was created using literature and the intervention procedure is presented below:~1. Active Communication and Evaluation~2. Daily Routine, Roles, and Occupational Performance~3. Strengths and Barriers~4. Intervention Program Development~5. Implementation of the intervention program~6. Feedback and Revision:
Study: NCT06269289

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard education brochure
Description: The control group will not be given web-based training, but will be given the standard asthma education brochure of the Ministry of Health.